Argatroban
A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.
분자량
508.6000 g/mol
LogP
1.30
TPSA
189.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …
2D 구조
Cite this structure
Embed this structure
SMILES
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1
InChI
InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
Molecular Formula
C23H36N6O5S
HBD / HBA
5 / 8
회전 가능 결합
9
무거운 원자
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A direct thrombin inhibitor that binds to and blocks the active site of thrombin, preventing it from converting fibrinogen to fibrin and forming blood clots. It is used to prevent and treat clotting in patients with heparin-induced thrombocytopenia.
Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.
Yes, Argatroban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1166. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 92722. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="argatroban"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/argatroban/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/argatroban/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/argatroban/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="argatroban"></drugfyi-drug>